Literature DB >> 6158957

Mithramycin treatment of Paget's disease of bone. Exploration of combined mithramycin-EHDP therapy.

W G Ryan, T B Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6158957     DOI： 10.1002/art.1780231013

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  6 in total

Review 1.  The contribution of Sir James Paget (1814-1894) to the study of rheumatic disease.

Authors:  W Buchanan
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 2.  Paget's disease of bone.

Authors:  C G Ooi; W D Fraser
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

3.  Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mithramycin: aetiological and therapeutic implications.

Authors:  A Long; T Loughlin; R P Towers; T J McKenna
Journal:  Ir J Med Sci       Date:  1988-07       Impact factor: 1.568

4.  Paget's disease of bone.

Authors:  G J Strewler
Journal:  West J Med       Date:  1984-05

Review 5.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 6.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.